A Well-Timed Allergan Options Trade

Dreary economic data rolled in ahead of the Fed chair's afternoon speech

 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

MIDDAY MARKET CHECK     6/25/2019
The #1 Biotech Stock to Own Today On September 10, 2018, a tiny biotech firm won a patent on a new treatment that can "Cut & Paste" any disease from your body. The Nobel Prize Committee called it "The Holy Grail of Medicine." This under-the-radar company is not yet a household name. Our research proves that anyone who gets in now could turn $1,000 into $1.57 Million >>>
Dow Trades Lower Ahead of Powell By Karee Venema Share On The Dow Jones Industrial Average (DJI) is modestly lower midday after a dismal batch of economic reports hit ahead of this afternoon's speech from Fed Chair Jerome Powell. Specifically, an S&P CoreLogic/Case Shiller report showed home prices rose at their slowest pace since August 2012, while separate data showed new home sales fell for a second straight month in May, and consumer confidence dropped to a lower-than-expected 121.5 in June, marking its weakest reading since September 2017. Traders are also keeping a cautious eye on geopolitical tensions between the U.S. and Iran, after President Donald Trump threatened "obliteration" on Twitter earlier. Continue reading for more on today's market, including:  The drug stock overdue for upgrades. Why Citi says it's time to buy GrubHub. Plus, a well-timed bullish options trade on Allergan; Krystal Biotech booms again; and FDA buzz sends Acer to the bottom of the Nasdaq. >> Continue reading...
LATEST HEADLINES
>> Software Stock's "Buy" Signal Has Never Been Wrong A bullish signal just sounded on the charts for Zscaler >> Put Buyers Should Jump on This Underpeforming Chip Stock Nvidia stock has suffered on the charts long term >> Analyst Says Microsoft Cloud Business Can't Compete with Amazon Jefferies really prefers Amazon's cloud business over Microsoft >> Credit Suisse: Time to Dump This Insurance Stock The brokerage firm set a Street-low price target on the stock, too >> GrubHub Stock Breaking Out After Citi Screams "Buy" GRUB is fresh off its third straight weekly win ADVERTISEMENT Turn $1,000 into $1.57 Million - with "Holy Grail of Medicine" On September 10, 2018, a tiny biotech firm won a patent on a new treatment that can "Cut & Paste" any disease from your body. The Nobel Prize Committee called it "The Holy Grail of Medicine." This under-the-radar company is not yet a household name. Our research proves that anyone who gets in now could turn $1,000 into $1.57 Million >>>
To ensure delivery of Schaeffer's Midday Market Check, add us to your contacts! For more information, please visit this link for further instructions. This email was sent to phanhoa1821960.trader@blogger.com because you are a registered subscriber to Schaeffer's Midday Market Check or have signed up to receive emails from www.schaeffersresearch.com. Don't want to receive Schaeffer's Midday Market Check? You can unsubscribe here. For more information about our privacy practices, please review our Privacy Policy or our Terms & Conditions. Have a question, comment or concern? We’ll respond quickest if you call (800) 448-2080, email, or write to:
		SCHAEFFER'S MIDDAY MARKET CHECK enews@schaeffer.com 5151 Pfeiffer Rd. Suite 250 Cincinnati, OH, 45242 USA 800-448-2080 www.schaeffersresearch.com